Selected Publications – Sorted by Cancer Type

See cancers by topic

Atre SY, Soulos PR, Kuderer NM, Gross CP, Baum LVM, Dinan MA, Lustberg MB. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Res Treat. 2024;207(3):541-550. PMID38816556.

Berger E, Long JB, Sheffrin M, Lindsay M, Richman IB. Use of surveillance mammography among older patients with a history of breast cancer. J Geriatr Oncol. 2024;15(3):101686. PMID38114335.

Dinan MA, Pitafi S, Greenup RA, Long JB, Gross CP. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Res Treat. 2023;198(1):177-181. PMID36542252.

Richman IB, Long JB, Soulos PR, Wang SY, Gross CP. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Ann Intern Med. 2023;176(9):1172-1180. PMID37549389.

Potnis KC, Ross JS, Aneja S, Gross CP, Richman IB. Artificial Intelligence in Breast Cancer Screening: Evaluation of FDA Device Regulation and Future Recommendations. JAMA Intern Med. 2022;182(12):1306-1312. PMID36342705.

Dinan MA, Pitafi S, Greenup RA, Long JB, Gross CP. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Res Treat. 2022;198(1):177-181. PMID36542252.

Richman IB, Long JB, Kyanko KA, Xu X, Gross CP, Busch SH. Insurance Coverage Mandates and the Adoption of Digital Breast Tomosynthesis. JAMA Netw Open. 2022; 5(3):e224208. PMID35333358.

Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X, Busch SH, Gross CP, Richman IB. Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women. J Gen Intern Med. 2022;37(8):1870-1876. PMID34595682.

Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP. Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years. JAMA Intern Med. 2021;181(12):1665-1668. PMID34459853

Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP. Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old. J Natl Cancer Inst. 2021;113(11):1515-1522. PMID33822120.

Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. J Clin Oncol. 2021;39(21):2386–2396. PMID32211582.

Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer. JAMA Netw Open. 2020; 3(11):e2027074. PMID33226431.

Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. JAMA Intern Med. 2020;180(5):799-801. PMID32202606.

Richman IB, Hoag JR, Xu X, Forman HP, Hooley R, Busch SH, Gross CP. Adoption of Digital Breast Tomosynthesis in Clinical Practice. JAMA Intern Med. 2019;179(7):1292-1295. PMID31233086.

Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. J Natl Compr Canc Netw. 2019 Jan;17(1):39-46. PMID30659128.

Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. J Clin Oncol. 2018;36(16):1619-1627. PMID29659329.

Avraham T, Gross CP, Killelea BK. Connections Between Hospital Financial Distress, Physician Incentive, and Patient Access to Breast Reconstruction. JAMA Surg. 2018;153(4):351-352. PMID29214317.

Lannin DR, Wang S. Are Small Breast Cancers Good because They Are Small or Small because They Are Good? N Engl J Med. 2017;376(23):2286-91. PMID28591529.

Pollack CE, Soulos PR, Herrin J, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang SY, Gross CP. The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. J Natl Cancer Inst. 2017;109(8). PMID28376191.

Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. J Natl Compr Canc Netw. 2017;15(3):346-354. PMID28275035.

Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ. Breast Cancer Res Treat. 2016;158(1):139-48. PMID27287780.

Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer. J Clin Oncol. 2016;34(4):321-8. PMID26628465.

Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Database. J Clin Oncol. 2015;33(36):4267-76. PMID26598753.

Evans SB, Yu JB. Hypofractionated radiation therapy versus conventionally fractionated radiation therapy for early-stage breast cancer: how do we choose? Future Oncol. 2015;11(15):2105-7. PMID26235175.

Wang EH, Mougalian SS, Soulos PR, Smith BD, Haffty BG, Gross CP, Yu JB. Adoption of Intensity Modulated Radiation Therapy For Early-Stage Breast Cancer From 2004 Through 2011. Int J Radiat Oncol Biol Phys. 2015;91(2):303-11. PMID25442334.

Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of breast cancer screening in the Medicare population: Clinical and economic implications. J Natl Cancer Inst. 2014;106(8). PMID25031307.

Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. J Natl Cancer Inst. 2014;106(3):dju008. PMID24598714.

Elmore JG, Gross CP. The Cost of Breast Cancer Screening in the United States: A Picture Is Worth... a Billion Dollars? Ann Intern Med. 2014;160(3):203-204-204.

Gross CP, Long JB, Ross JS, Abu-Khalaf M, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The Cost of Breast Cancer Screening in the Medicare Population. JAMA Intern Med. 2013;173(3):220-6. PMID23303200.

Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the impact of a cooperative group trial on breast cancer care in the Medicare population. J Clin Oncol. 2012;30(14):1601-7. PMID22393088.

Fox JP, Zikmund-Fisher BJ, Gross CP. Older patient experiences in the mammography decision-making process. Arch Int Med. 2012;172(1):62-4. PMID22232149.

Smani S, Sundaresan V, Lokeshwar SD, Choksi AU, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman MS. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Explor Target Antitumor Ther. 2024;5(4):981-996. PMID39280242.

Ajjawi I, Loeb S, Cooperberg MR, Catalona WJ, Gross CP, Ma X, Leapman MS. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA. 2024;332(23):2033-2036. PMID39565605.

Kunst N, Long JB, Westvold S, Sprenkle PC, Kim IY, Saperstein L, Rabil M, Ghaffar U, Karnes RJ, Ma X, Gross CP, Wang SY, Leapman MS. Long-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer. JAMA Netw Open. 2024;7(10):e2440591. PMID39441595.

Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco JI, Washington SL, Renzulli JF II,, Sprenkle P, Kim IY, Leapman MS. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urol Oncol. 2024;42(2):28.e9-28.e20. PMID38161105.

‌Leapman MS, Ho J, Liu Y, Filson CP, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Ross AE, Sprenkle PC. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Netw Open. 2024;7(6):e2417274. PMID38874922.

Leapman MS, Sutherland R, Gross CP, Ma X, Seibert TM, Cooperberg MR, Catalona WJ, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. BJUI Compass. 2023;5(1):142-149. PMID38179031.

Sutherland R, Gross CP, Ma X, Jeong F, Seibert TM, Cooperberg MR, Catalona WJ, Ellis SD, Loeb S, Schulman-Green D, Leapman MS. 'It Just Makes Sense to Me': A qualitative study exploring patient decision-making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass. 2024;5(6):593-601. PMID38873351.

Sundaresan VM, Wang R, Long JB, Sprenkle PC, Seibert TM, Loeb S, Cooperberg MR, Catalona WJ, Ma X, Gross CP, Leapman MS. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urol Pract. 2024:11(6):965-973. PMID39196719.

Demkowicz PC, Buck MB, Nie J, Marks VA, Wheeler SB, Dinan MA, Gross CP, Leapman MS. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology. 2024;192:19-27. PMID38901803.

Yu JB, DeStephano DM, Jeffers B, Horowitz DP, Soulos PR, Gross CP, Cheng SK. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. J Clin Oncol. 2024;42(16):1943-1952. PMID38507655.

Leapman MS, Thiel CL, Gordon IO, Nolte AC, Perecman A, Loeb S, Overcash M, Sherman JD. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. Eur Urol. 2023;83(5):463-471. PMID36635108.

Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg MR, Sprenkle P, Leapman MS. Prostate Cancer Risk Stratification Using Magnetic Resonance Imaging-Ultrasound Fusion versus Systematic Prostate Biopsy. JNCI Cancer Spectr. 2023;7(6):pkad099. PMID38085220.

Leapman MS, Wang R, Loeb S, Seibert TM, Gaylis FD, Lowentritt B, Brown GA, Chen R, Lin D, Witte J, Cooperberg MR, Catalona WJ, Gross CP, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. J Urol. 2023;209(4):710-718. PMID36753746.

Leapman MS, Stone K, Wadia R, Park LS, Gilbert CL, Goetz MB, Bedimo R, Rodriguez-Barradas M, Shebl F, Justice AC, Brown ST, Crothers K, Sigel KM. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV. J Urol. 2022; 207(2):324-332. PMID34555924.

Laditi F, Nie J, Jones T, Leapman MS. Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States. Eur Urol Focus. 2022;8(4):910-912. PMID35778364.

Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncol. 2022;8(1):41-47. PMID34762100.

Leapman MS, Dinan M, Pasha S, Long J, Washington 3rd SL, Ma X, Gross CP. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. JAMA Oncol. 2022;8(5):687-696. PMID35238879.

Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Netw Open. 2021;4(10): e2128646. PMID34623406.

Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncol. 2021;7(1):52-58. PMID33237277.

Yu JB, Hamstra D. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Oncology. 2017;31(11):830-2. PMID29179251.

Yu JB. Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales. J Clin Oncol. 2017;35(17):1867-1869. PMID28355114.

Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, and Yu JB. Patient-reported quality of life after stereotactic body radiation therapy vs. moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016;121(2)294-298. PMID27890426.

Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D'Amico AV, Yu JB. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. J Natl Cancer Inst. 2016;109(6). PMID28040795.

Wang EH, Gross CP, Tilburt JC, Yu JB, Nguyen PL, Smaldone MC, Shah ND, Abouassally R, Sun M, Kim SP. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. JAMA Intern Med. 2015;175(5):792-9. PMID25751604.

Makarov DV, Sen S, Soulos PR, Gold HT, Yu JB, Ross J, Gross CP. Regional-level inappropriate imaging rates for prostate and breast cancers are correlated: Potential Implications for Choosing Wisely. JAMA Oncol. 2015;1(2):185-194. PMID26181021.

Raldow AC, Presley CJ, Yu JB, Sharma R, Cramer LD, Soulos PR, Long JB, Makarov DV, Gross CP. The relationship between clinical benefit and receipt of curative therapy for prostate cancer. Arch Intern Med. 2012;172(4):362-3. PMID22371925.

Ross JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med. 2012;172(2):1601-3. PMID22987029.

DeSantis W, Ayoade O, Caturegli G, Boffa DJ. Lung Cancer Screening at US Hospitals for People Lacking Primary Care. JAMA Netw Open. 2024;7(10):e2442373. PMID39480427.

Amini A, Park HS. Fibrosis or Recurrence After Lung Stereotactic Body Radiation Therapy: A Proposed Decision Tree. Pract Radiat Oncol. 2024;14(6):e467-e469. PMID39487014.

Nemeth A, Canavan ME, Zhan PL, Udelsman BV, Ely S, Wigle DA, Martin L, Jeffrey Yang CF, Boffa DJ, Dhanasopon AP. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open. 2024;20:141-150. PMID39296459.

Poghosyan H, Richman IB, Sarkar S, Presley CJ. Lung cancer screening use among screening-eligible adults with disabilities. J Am Geriatr Soc. 2024;72(4):1155-1165. PMID38357789.

Jairam V, Soulos PR, K.C. M, Gross CP, Slotman BJ, Chiang AC, Park HS. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Adv Radiat Oncol. 2023;9(4): 101413. PMID38778819.

Li AX, Canavan ME, Ermer T, Maduka RC, Zhan P, Pichert MD, Boffa DJ, Blasberg JD. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. Ann Thorac Surg. 2024;117(1):163-171. PMID37774762.

Udelsman BV, Canavan ME, Zhan PL, Ely S, Park HS, Boffa DJ, Mase VJ Jr. Overall survival in low-comorbidity patients with stage I non-small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. J Thorac Cardiovasc Surg. 2024;167(3):822-833. PMID37500052.

Sasse A, Oh P, Saeed N, Yang DX, Hayman TJ, Knowlton CA, Peters GW, Campbell A, Laird J, Housri N, Park HS. Dose-volume predictors of radiation pneumonitis following thoracic hypofractionated radiotherapy. Pract Radiat Oncol. 2024;14(2):e97-e104. PMID37984711.

Li AX, Canavan ME, Ermer T, Maduka RC, Zhan P, Pichert MD, Boffa DJ, Blasberg JD. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. Ann Thorac Surg. 2024;117(1):163-171. PMID37774762.

Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life care trajectories among older adults with lung cancer. J Geriatr Oncol. 2023;14(1):101381. PMID36202695.

Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP. Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncol. 2023;9(3):334-341. PMID36701150.

Gross CP, Meyer CS, Ogale S, Kent M, Wong WB. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC. J Natl Compr Canc Netw. 2022;20(5):479-487. PMID35545174.

Dhanasopon AP, Boffa DJ. Defining Relevancy in Patient-Reported Outcomes for Lung Cancer Surgery. Ann Surg Oncol. 2022;29(9):5367-5368. PMID35503390.

Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Netw Open. 2022;5(8):e2224478. PMID35925606.

Saffarzadeh AG, Canavan M, Resio BJ, Walters SL, Flores KM, Decker RH, Boffa DJ. Optimal Radiation Dose for Stage III Lung Cancer-Should "Definitive" Radiation Doses Be Used in the Preoperative Setting? JTO Clin Res Rep. 2021;2(8):100201. PMID34590044.

Li AX, Flores K, Canavan ME, Boffa DJ, Blasberg JD. Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules. Ann Thorac Surg. 2022;113(2):421-428. PMID33684345.

Presley CJ, Kaur K, Han L, Soulos PR, Zhu W, Corneau E, O'Leary JR, Chao H, Shamas T, Rose MG, Lorenz KA, Levy CR, Mor V, Gross CP. Aggressive End-of-Life Care in the Veterans Health Administration versus Fee-for-Service Medicare among Patients with Advanced Lung Cancer. J Palliat Med. 2022;25(6):932-939. PMID35363053.

Li AX, Resio BJ, Canavan ME, Papageorge M., Boffa DJ, Blasberg JD. Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis. J Thorac Dis. 2021;13(6):3409–3419. PMID34277037.

Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncol. 2020;6(11):1-10. PMID32940636.

Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2020;3(6):e207205. PMID32511721.

Giri S, Huntington SF. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(7):1066. PMID31095252.

Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. JAMA. 2018;320(5):469-477. PMID30088010.

Andreano A, Peake MD, Janes SM, Valsecchi MG, Pritchard-Jones K, Hoag JR, Gross CP. The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012. J Thorac Oncol. 2018;13(7):904-914. PMID29727739.

Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncol. 2017;3(5):610-619. PMID28056112.

Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):314-322. PMID27720827.

Sandler BJ, Wang Z, Hancock JG, Boffa DJ, Detterbeck FC, Kim AW. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. Ann Surg Oncol. 2016;23(2):638-45. PMID26474557.

Salazar MC, Rosen JE, Arnold BN, Thomas DC, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Adjuvant Chemotherapy for T3 Non-Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe. J Thorac Oncol. 2016;11(7):1090-100. PMID27013407.

Rosen JE, Keshava HB, Yao X, Kim AW, Detterbeck FC, Boffa DJ. The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database. Ann Thorac Surg. 2016;101(5):1850-5. PMID27041452.

Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. J Thorac Oncol. 2016 Jul;11(7):1121-31. PMID27103511.

Presley CJ, Gross CP, Lilenbaum RC. Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. J Clin Oncol. 2016;34(13):1438-42. PMID27001591.

Wang EH, Rutter CE, Corso CD, Decker RH, Wilson LD, Kim AW, Yu JB, Park HS. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015;10(6):937-43. PMID25738221.

Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(25):2727-34. PMID26101240.

Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD, Husain ZA, Lilenbaum RC, Yu JB, Decker RH. Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2015;33(36):4240-6. PMID26481366.

Wang R, Neparidze N, Ma X, Colditz GA, Chang SH, Wang SY. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Med. 2024;13(3):e6915. PMID38234237.

Shimer S, Allen OS, Yang C, Canavan ME, Westvold SJ, Kim N, Morillo J, Parker T, Wallace N, Smith CB, Adelson KB. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. J Palliat Med. 2024;27(7):879-887. PMID38990245.

Di M, Potnis KC, Long JB, Isufi I, Foss F, Seropian S, Gross CP, Huntington SF. Costs of care during chimeric antigen receptor T-cell therapy in relapsed/refractory B cell lymphomas. JNCI Cancer Spectr. 2024;8(4):pkae059. PMID39115391.

Podoltsev NA, Wang R, Shallis RM, Stempel JM, Di M, Neparidze N, Zeidan AM, Huntington SF, Giri S, Hull SC, Gore SD, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Med. 2023;12(18):18889-18900. PMID37702132.

Di M, Long JB, Kothari SK, Sethi T, Zeidan AM, Podoltsev NA, Shallis RM, Wang R, Ma X, Huntington SF. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica. 2023;108(8):2218-2223. PMID36655436.

Rodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R. Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncol Pract. 2022;18(7):e1060-e1068. PMID35427182.

Neparidze N, Wang R,Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia. 2022;36(8):2136-2139. PMID35761025.

Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. J Clin Oncol. 2021;39(10):1119–1128. PMID33411586.

Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood.136(17):1946-1955. PMID32518952.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The Impact of Hydroxyurea on Survival and Risk of Thrombosis among Older Patients with Essential Thrombocythemia. J Natl Compr Canc Netw. 2019;17(3):211-219. PMID30865915.

Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician experience and risk of rituximab discontinuation in older adults with non-Hodgkin’s lymphoma. J Natl Compr Canc Netw. 2019;17(10):1194-1202. PMID31590152.

Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131(7):818-821. PMID29259002.

Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J. 2018;8(6):55. PMID29891916.

Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. J Clin Oncol. 2018;36(28):2879-2886. PMID30113885.

Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. J Clin Oncol. 2017;35(30):3417-3424. PMID28783450.

Rogne T, Wang R, Wang P, Deziel NC, Metayer C, Wiemels JL, Chen K, Warren JL, Ma X. High ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study. Lancet Planet Health. 2024;8(7):e506-e514. PMID38969477.

Lindsay ME, de Oliveira S, Sciacca K, Lindvall C, Ananth PJ. Harnessing Natural Language Processing to Assess Quality of End-of-Life Care for Children With Cancer. JCO Clin Cancer Inform. 2024; e2400134. PMID39265122.

Ananth P, Mun S, Reffat N, Kang SJ, Pitafi S, Ma X, Gross CP, Wolfe J. Refining Patient-Centered Measures of End-of-Life Care Quality for Children With Cancer. JCO Oncol Pract. 2022;18(3):e372-e382. PMID34613797.

Ananth P, Wolfe J, Johnston EE. Charting a path to high-quality end-of-life care for children with cancer. Cancer. 2022;128(20):3586-3592. PMID36006762.

Ananth P. Reenvisioning End-of-Life Care Quality Measurement for Adolescents and Young Adults With Cancer-Novel Patient-Centered Indicators and Approaches. JAMA Netw Open. 2021;4(8): e2122323. PMID34424309.

Cote DJ, Wang R, Morimoto LM, Metayer C, Zada G, Wiemels JL, Ma X. Association between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001-2015. Cancer Causes Control. 2023;34(9):757-768. PMID37225897.

Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. J Neurosurg. 2022;1-11. PMID35907197.

Forman R, Long JB, Westvold SJ, Agnish K, McManus HD, Leapman MS, Hurwitz ME, Spees LP, Wheeler SB, Gross CP, Dinan MA. Cost trends of Metastatic Renal Cell Carcinoma Therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectr. 2024;pkae067. PMID39133171.

Rahman SN, Long JB, Westvold SJ, Leapman MS, Spees LP, Hurwitz ME, McManus HD, Gross CP, Wheeler SB, Dinan MA. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2024;7(4):e248747. PMID38687479.

Chow RD, Long JB, Hassan S, Wheeler SB, Spees LP, Leapman MS, Hurwitz ME, McManus HD, Gross CP, Dinan MA. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum. 2023;7(3):pkad036. PMID37202354.

Dzimitrowicz HE, Wilson LE, Jackson BE, Spees LP, Baggett CD, Greiner MA, Kaye DR, Zhang T, George D, Scales CD Jr, Pritchard JE, Leapman MS, Gross CP, Dinan MA, Wheeler SB. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncol Pract. 2023. 19(2):e213-e227. PMID36413741.

Dinan MA, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Kaye D, George D, Scales Jr CD Baggett CD, Gross CP, Leapman MS, Wheeler SB. Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). Urology. 2022;168:129-136. PMID35878815.

Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. J Geriatr Oncol. 2022;13(5):635-643. PMID34996724.

Kaye DR, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Pollack CE, George D, Scales CD Jr, Baggett CD, Gross CP, Leapman MS, Wheeler SB, Dinan MA. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. J Geriatr Oncol. 2022;13(5):614-623. PMID35125336.

Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales Jr CD, Pritchard JE, Leapman M, Gross CP, Dinan MA. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Med. 2021;10(19):6653-6665. PMID34480518.

Siddique S, Wang R, Yasin F, Gaddy JJ, Zhang L, Gross CP, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Netw Open. 2024;7(10):e2436358. PMID39361285.

Siddique S, Baum LVM, Deziel NC, Kelly JR, Warren JL, Ma X. Using a Bayesian analytic approach to identify county-level ecological factors associated with survival among individuals with early-onset colorectal cancer. PLoS One. 2024;19(10):e0311540. PMID39471191.

Rahman SN, Lokeshwar SD, Syed JS, Javier-Desloges JF, Press BH, Choksi AU, Rajwa P, Pradere B, Ploussard G, Kim JW, Monaghan TF, Renzulli JR, Shariat SF, Leapman MS. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urol Oncol. 2023;41(2):107.e1-107.e8. PMID36481253.

Xu X, Chen L, Nunez-Smith M, Clark M, Wright JD. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. J Natl Cancer Inst. 2023;115(6):636-643. PMID36788453.

Xu X, Chen L, Nunez-Smith M, Clark M, Wright JD. Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data. PLoS One. 2023;18(9):e0289692. PMID37682914.

Xu X, Chen L, Nunez-Smith M, Clark M, Ferris JS, Hershman DL, Wright JD. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecol Oncol. 2023;180:118-125. PMID38091770.

Xu X, Lin H, Wright JD, Gross CP, Boscoe FP, Hutchison LM, Schwartz PE, Desai VB. Association between power morcellation and mortality in women with unexpected uterine cancer undergoing hysterectomy or myomectomy. J Clin Oncol. 2019 Dec 10;37(35):3412-3424. PMID31518176.

Udelsman BV, Ermer T, Ely S, Canavan ME, Zhan P, Boffa DJ, Blasberg JD. Assessment of a collaborative treatment model for trimodal management of esophageal cancer. J Thorac Dis. 2023;15(9):4668-4680. PMID37868899.

Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. J Natl Compr Canc Netw. 2020;18(6):729-736. PMID32502978.

Jain S, Long JB, Rao V, Law AC, Walkey AJ, Prsic E, Lindenauer PK, Krumholz HM, Gross CP. Trends in use of intensive care during hospitalizations at the end-of-life among older adults with advanced cancer. J Am Geriatr Soc. 2024;72(12):3840-3848. PMID39090970.

Li H, Huntington SF, Gross CP, Wang SY. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLoS One. 2024;19(4):e0300789. PMID38625861.

Maduka RC, Canavan ME, Walters SL, Ermer T, Zhan PL, Kaminski MF, Li AX, Pichert MD, Salazar MC, Prsic EH, Boffa DJ. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Med. 2024;13(9):e7028. PMID38711364.

Richman IB, Soulos PR, Lin H, Aminawung JA, Oladeru OT, Puglisi LB, Wang EA, Gross CP. Incarceration and Screen-Detectable Cancer Diagnosis among Adults in Connecticut. J Natl Cancer Inst. 2024;116(3):485-489. PMID37991935.

Baum LVM, KC M, Soulos PR, Jeffery MM, Ruddy KJ, Lerro CC, Lee H, Graham DJ, Rivera DR, Leapman MS, Jairam V, Dinan MA, Gross CP, Park HS. Trends in New and Persistent Opioid Use in Older Adults with and without Cancer. J Natl Cancer Inst. 2023;116(2):316-323. PMID37802882.

Canavan ME, Wang X, Ascha MS, Miksad RA, Showalter TN, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncol. 2024;10(7):887-895. PMID38753341.

Thanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero MH, Huntington SF, Jeffery MM, Jones L, Noble B, Paludo J, Powers B, Ross JS, Ritchie JD, Ruddy K, Schellhorn S, Tarver M, Dueck AC, Gross CP. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open. 2024;14(1):e074030. PMID38199641.

Aminawung JA, Soulos PR, Oladeru OT, Lin HJ, Gonsalves L, Puglisi LB, Hassan S, Richman IB, Wang EA, Gross CP. Cancer incidence among incarcerated and formerly incarcerated individuals: a statewide retrospective cohort study. Cancer Med. 2023;12(14):15447-15454. PMID37248772.

Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, Gross CP, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. J Clin Oncol. 2023;41(30):4729-4738. PMID37339389.

Ananth P, Lindsay M, Mun S, McCollum S, Shabanova V, de Oliveira S, Pitafi S, Kirch R, Ma X, Gross CP, Boyden JY, Feudtner C, Wolfe J. Parent Priorities in End-of-Life Care for Children With Cancer. JAMA Netw Open. 2023;6(5):e2313503. PMID37184834.

KC M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang SY, Silber A, Leapman MS, Leeds I, Wheeler SB, Spees LP, Gross CP, Lustberg M, Greenup RA, Justice AC, Oeffinger KC, Dinan MA. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Netw Open. 20233;6(7):e2323115. PMID37436746.

Marks VA, Hsiang WR, Nie J, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Berger ER, Boffa DJ, Leapman MS. Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis. JAMA Netw Open. 2022;1;5(7):e2222214. PMID35838668.

Chow RD, Bradley EH, Gross CP. Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries. JAMA Health Forum. 2022;3(5):e221229. PMID35977250.

Salazar MC, Canavan ME, Holaday LW, Billingsley KG, Ross J, Boffa DJ, Gross CP. Access to High-Volume Hospitals for High-Risk Cancer Surgery for Racial and Ethnic Minoritized Groups. JNCI Cancer Spectr. 2022;6(2):pkac024. PMID35603855.

Hung P, Cramer LD, Pollack CE, Gross CP, Wang SY. Primary care physician continuity, survival, and end-of-life care intensity. Health Serv Res. 2022; 57(4):853-862. PMID34386976.

Oladeru OT, Aminawung JA, Lin HJ5, Gonsalves L, Puglisi L, Mun S, Gallagher C, Soulos P, Gross CP, Wang EA. Incarceration status and cancer mortality: A population-based study. PLoS One. 2022;17(9):e0274703. PMID36112653.

Canavan ME, Wang W, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life-Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncol. 2022;8(12):1847-1849. PMID36264566.

Zhan PL, Canavan ME, Ermer T, Pichert MD, Li AX, Maduka RC, Boffa DJ. Association of insurance status and extent of organ involvement with survival among patients with Stage IV cancer. JAMA Netw Open. 2022;5(6):e2217581. PMID35713907.

Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Netw Open. 2022;5(6):e2219535. PMID35771575.

Gould Rothberg BE, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB. Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncol Pract. 2022;18(1):e129-e136. PMID34383579.

Ermer T, Walters SL, Canavan ME, Salazar MC, Li AX, Doonan M, Boffa DJ. Understanding the Implications of Medicaid Expansion for Cancer Care in the US: A Review. JAMA Oncol. 2022;8(1):139-148. PMID34762101.

Salazar MC, Kaminski MF, Canavan ME, Maduka RC, Li AX, Ermer T, Boffa DJ. Baseline Evaluation of Cancer Mortality in US States that Expanded Medicaid vs Nonexpansion States. JAMA Oncol. 2021;7(9):1394-1395. PMID34292299.

Talcott WJ, Yu JB, Gross CP,Park HS. Social Connectedness Among Medicare Beneficiaries Following the Onset of the COVID-19 Pandemic. JAMA Intern Med. 2021;181(9):1245–1248. PMID34047760.

Lopez L 3rd, Dhodapkar M, Gross CP. US Nonprofit Hospitals' Community Health Needs Assessments and Implementation Strategies in the Era of the Patient Protection and Affordable Care Act. JAMA Newt Open. 2021;4(8):e2122237. PMID34427683.

Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Newt Open. 2021;4(4):e217063. PMID33877309.

Mahal AR, Cramer LD, Wang EH, Wang S, Davidoff AJ, Gross CP, Yu JB. Did quality of life for older cancer survivors improve with the turn of the century in the United States? J Geriatr Oncol. 2021;12(1):102–105. PMID32535014.

Cheng E, Soulos PR, Irwin ML, Cespedes Feliciano EM, Presley CJ, Fuchs CS, Meyerhardt JA, Gross CP. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. JAMA Netw Open. 2021;4(12):e2139593. PMID34919133.

Jairam V, Yang DX, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS. Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population. J Natl Cancer Inst. 2021;113(3):274-281. PMID32785685.

Salazar MC, Canavan ME, Walters SL, Herrin J, Schwartz JL, Leapman M, Boffa DJ. Evaluation of Cancer Care After Medicaid Expansion Under the Affordable Care Act. JAMA Netw Open. 2020; 3(9):e2017544. PMID32990734.

Mahal AR, Cramer LD, Wang EH, Wang SY, Davidoff AJ, Gross CP, Yu JB. Did quality of life for older cancer survivors improve with the turn of the century in the United States? J Geriatr Oncol. 2020; 12(1):102-105. PMID32535014.

Jairam V, Yang DX, Yu JB, Park HS. Emergency Department Visits for Opioid Overdoses Among Patients With Cancer. J Natl Cancer Inst. 2020; PMID31845985.

Jairam C, Yang DX, Verma V, Yu JB, Park HS. National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. JAMA Netw Open. 2020;3(8):e2013605. PMID32804217.

Huntington SF, Davidoff AJ, Gross CP. Precision medicine in oncology II: Economics of targeted agents and Immuno-Oncology drugs. J Clin Oncol. 2020;38(4):351-358. PMID31804866.

Boffa DJ, Mallin K, Herrin J, Resio B, Salazar MC, Palis B, Facktor M, McCabe R, Nelson H, Shulman LN. Survival After Cancer Treatment at Top-Ranked US Cancer Hospitals vs Affiliates of Top-Ranked Cancer Hospitals. JAMA Netw Open. 2020;3(5):e203942. PMID32453382.

Jairam V, Lee V, Park HS, Thomas CR Jr, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncol. 2019;5(7):1028-1035. PMID30946433.

Resio BJ, Hoag JR, Chiu AS, Monsalve A, Sathe T, Xu X, Boffa DJ. Variations in Surgical Safety According to Affiliation Status With a Top-Ranked Cancer Hospital. JAMA Oncol. 2019;5(9):1359-1362. PMID31294746.

Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. J Natl Cancer Inst. 2018; 110(1). PMID28922780.

O’Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncol. 2018; 4(8):e180798. PMID29800974.

Johnson SB, Park HS, Gross CP, Yu JB. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncol. 2018;4(10):1375-1381. PMID30027204.

Chiu AS, Resio B, Hoag JR, Monsalve AF, Blasberg JD, White MA, Boffa DJ. US Public Perceptions About Cancer Care Provided by Smaller Hospitals Associated With Large Hospitals Recognized for Specializing in Cancer Care. JAMA Oncol. 2018;4(7):1008-1009. PMID29852033.

Kadan-Lottick NS, Ross WL, Mitchell HR, Rotatori J, Gross CP, Ma X. Randomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans. J Natl Cancer Inst. 2018;110(12):1352-1359. PMID29771337.

O'Connor JM, Sedghi T, Dhodapkar M, Kane MJ, Gross CP. Factors Associated With Cancer Disparities Among Low-, Medium-, and High-Income US Counties. JAMA Netw Open. 2018;1(6):e183146. PMID30646225.

Encinosa W, Davidoff AJ. Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations. JAMA Oncol. 2017;3(3):320-326. PMID27632203.

Jairam V, Yu JB. Examination of Industry Payments to Radiation Oncologists in 2014 Using the Centers for Medicare and Medicaid Services Open Payments Database. Int J Radiat Oncol Biol Phys. 2016;94(1):19-26. PMID26547386.

Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. J Natl Compr Canc Netw. 2016;14(8):1001-8. PMID27496116.

Leapman MS. Embracing Challenges and Opportunities Posed by New Technologies in Urologic Care. Urol Pract. 2024;11(1):7-8. PMID37747948.

Richman IB, Gross CP. Progress in Lung Cancer Screening Adoption. JAMA Intern Med. 2024;184(8):902-903. PMID38857025.

Richman IB, Gross CP, Wang EA. Cancer and incarceration: a call for action. Lancet Oncol. 2024;25(5):530-531. PMID38697151.

Gross CP, Corbie G. Physicians in Private Equity Practices-Canaries in a Coal Mine? JAMA Intern Med. 2024;184(5):580-581. PMID38466292.

Zhang GY, Gross CP. Protecting Patients by Reducing Diagnostic Error. JAMA Intern Med. 2024;184(2):173. PMID38190151.

Gross CP, Durant RW. Tracking Physical Activity One Step at a Time. JAMA Intern Med. 2024;184(7):726. PMID38767900.

Richman IB, Battaglia TA. Evaluating Supplemental Breast Cancer Screening With Simulation Modeling. JAMA Intern Med. 2024;184(10):1232-1233. PMID39186297.

Dinan MA, Wheeler SB. Zillow MD: Do housing prices predict cancer survival? JNCI Cancer Spectr. 2023;7(6):pkad086. PMID37965909.

Richman IB, Fendrick AM. Eliminating Financial Barriers to Breast Cancer Screening-When Free Is Not Really Free. JAMA Netw Open. 2023;6(3):e234898. PMID36972055.

Gross CP, Kraschel KL, Emanuel EJ. Holding Medical Professional Society Scientific Meetings Only in States That Protect Abortion Rights-Clinical and Ethical Considerations. JAMA Intern Med. 2023;183(4):283-284. PMID36848080.

Crosson FJ, Ostrer IR, Gross CP. Private Equity in US Health Care-Now Cradle to Grave? JAMA Intern Med. 2023;183(6):511-512. PMID37126342.

Richman I, Tessier-Sherman B, Galusha D, Oladele CR, Wang K. Breast Cancer Screening During the COVID-19 Pandemic: Moving from Disparities to Health Equity. J Natl Cancer Inst. 2023;115(2):139-145. PMID36069622.

Potnis KC, Huntington SF. When competition is not enough: leveraging US policies to curb oral anticancer drug costs. Lancet Oncol. 2022;23(7):836-837. PMID35772451.

Gross CP, Dusetzina SB. Stemming Medicare Spending on Discarded Drugs-Waste Not, Want Not? JAMA Intern Med. 2022;183(2):93. PMID36534375.

Gross CP, Rosekind MR. Driving Safety After an Acute Illness-This Is Our Lane. JAMA Intern Med. 2022;182(9):942. PMID35913724.

Gaddy JJ, Gross CP. Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment: Time to Stop Tinkering Around the Edges. JAMA Oncol. 2022;8(12):1792-1793. PMID36301581.

Ostrer IR, Gross CP. Paying for Cancer Drugs-Getting What We Are (Prohibited From) Bargaining for. JAMA Intern Med. 2022;182(12):1245. PMID36315133.

Park HS. Leveraging Surgical Case Volume in Improving Cancer Care Outcomes: Where Do We Go From Here? J Natl Compr Canc Netw. 2021;19(5):577–579. PMID34030129.

Salazar MC, Gross CP. Improving Surgical Cancer Care: A Rising Tide May Lift All Boats, Yet Inequity Persists. JAMA Netw Open. 2020;3(12):e2027809. PMID33270119.

Richman IB, Gross CP. New Breast Cancer Screening Technologies in Older Women-Is It Time to Pump the Brakes? JAMA Intern Med. 2019;79(3):289-290. PMID30640376.

Lehman R, Gross CP. An International Perspective on Drugs for Cancer: The Best of Times, the Worst of Times. JAMA Intern Med. 2019;179(7):913-914. PMID31135827.

Gross CP, Gluck AR. Soaring Cost of Cancer Treatment: Moving Beyond Sticker Shock. J Clin Oncol. 2018;36(4):305-307. PMID29236571.

Zeidan AM, Gore SD, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box. J Clin Oncol. 2017;35(28):3264. PMID28787256.

Gross CP, Emanuel EJ. A Call for Value in Cancer Research. JAMA Oncol. 2016;2(1):11-2. PMID26447464.

Neugut AI, Gross CP. Targeting the Cancer Moonshot. JAMA Oncol. 2016;2(4):421-2. PMID26940477.

Huntington SF, Gross CP. Negative Studies in Cancer Research: Why the Negativity? JAMA Oncol. 2016;2(7):865-6. PMID26967116.

Huntington SF, Davidoff AJ. High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. J Clin Oncol. 2016;34(36):4307-4309. PMID27998230.

Howard DH, Gross CP. Producing Evidence to Reduce Low-Value Care. JAMA Intern Med. 2015;175(12):1893-4. PMID26457957.

Gross CP. Cancer screening in older persons: A new age of wonder. JAMA Intern Med. 2014;174(10):1565-7. PMID25133660.